^
    15h
    PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, Guangxi Medical University | Trial completion date: Mar 2026 --> Mar 2029
    Trial completion date
    |
    cisplatin
    18h
    Post-radiation targeting of TIGIT and CD96 improved immunotherapy efficacy in head and neck squamous cell carcinoma. (PubMed, Mol Med)
    Our findings suggest that TIGIT and CD96 could be markers of the clinical stage and treatment response of HNSCC. Therefore, administering anti-TIGIT and anti-CD96 after radiotherapy may provide a novel approach for incorporating immunoradiotherapy into HNSCC treatment.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • PVR (PVR Cell Adhesion Molecule) • CD96 (CD96 Molecule) • NECTIN1 (Nectin Cell Adhesion Molecule 1) • NECTIN2 (Nectin Cell Adhesion Molecule 2)
    18h
    H3K36 Methylation as a Guardian of Epigenome Integrity. (PubMed, Nat Commun)
    Parallel analyses in human HNSCC cells overexpressing the H3K36M oncohistone reveal conserved disruptions to the epigenome and chromatin architecture. Together, these results establish H3K36 methylation as a pivotal regulator of chromatin state and genomic structure.
    Journal
    |
    SUV39H1 (SUV39H1 Histone Lysine Methyltransferase)
    18h
    CCR7 Promotes Neutrophil Recruitment and N2 Polarization Through Regulation of IL-16 in Head and Neck Squamous Cell Carcinoma. (PubMed, Int Dent J)
    These findings establish CCR7 as a key regulator of IL-16-mediated neutrophil recruitment and N2 polarization in HNSCC, highlighting its potential as a therapeutic target to remodel the immunosuppressive tumour microenvironment.
    Journal
    |
    CCR7 (Chemokine (C-C motif) receptor 7) • IL16 (Interleukin 16)
    18h
    INTERLINK-1: Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov)
    P3, N=370, Active, not recruiting, AstraZeneca | Trial completion date: Sep 2025 --> Sep 2026
    Trial completion date • Checkpoint inhibition
    |
    Erbitux (cetuximab) • monalizumab (IPH2201)
    18h
    Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=67, Completed, Washington University School of Medicine | Trial completion date: Dec 2025 --> Jul 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    Keytruda (pembrolizumab) • cisplatin
    18h
    OrigAMI-5: A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • 5-fluorouracil • Rybrevant (amivantamab-vmjw)
    19h
    VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1/2, N=242, Recruiting, VM Oncology, LLC | Phase classification: P1 --> P1/2 | N=82 --> 242 | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    Keytruda (pembrolizumab) • VMD-928
    19h
    FAISA-CORPPS: Feasibility Study CORPPS (clinicaltrials.gov)
    P=N/A, N=30, Completed, University Hospital, Lille | Not yet recruiting --> Completed
    Trial completion
    19h
    Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=60, Completed, Guangxi Medical University | Unknown status --> Completed | Trial completion date: Jun 2022 --> Oct 2025
    Trial completion • Trial completion date
    |
    cisplatin • 5-fluorouracil • albumin-bound paclitaxel
    19h
    REDEFINE: Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II) (clinicaltrials.gov)
    P2, N=23, Recruiting, Jiangxi Provincial Cancer Hospital
    New P2 trial
    21h
    KEYNOTE-C34: Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (clinicaltrials.gov)
    P2, N=171, Completed, Immutep S.A.S. | Active, not recruiting --> Completed
    Trial completion
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)